# Accendra Health Inc: financial statements, quarterly

ACH · NYSE · CIK 75252 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ach.md) · [Financials](/companies/ach/financials.md) · [Filings](/companies/ach/filings.md) · [Insiders](/companies/ach/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ach/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,592](/filings/0001558370-24-014255.md) | [(5,125) d](/filings/0001104659-26-018169.md) | [2,613](/filings/0001558370-25-006964.md) | [660](/filings/0001558370-25-011059.md) | [687](/filings/0001104659-25-104506.md) | [695 d](/filings/0001104659-26-018169.md) | [674](/filings/0001104659-26-058465.md) | [682](/filings/0001104659-26-093177.md) | [697](/filings/0001104659-25-104506.md) | [709 d](/filings/0001104659-26-018169.md) | [628](/filings/0001104659-26-058465.md) | [613](/filings/0001104659-26-093177.md) |
| Cost of revenue | $m | [2,053](/filings/0001558370-24-014255.md) | [(4,787) d](/filings/0001104659-26-018169.md) | [2,077](/filings/0001558370-25-006964.md) | [344](/filings/0001558370-25-011059.md) | [355](/filings/0001104659-25-104506.md) | [362 d](/filings/0001104659-26-018169.md) | [355](/filings/0001104659-26-058465.md) | [357](/filings/0001104659-26-093177.md) | [375](/filings/0001104659-25-104506.md) | [386 d](/filings/0001104659-26-018169.md) | [350](/filings/0001104659-26-058465.md) | [350](/filings/0001104659-26-093177.md) |
| Gross profit | $m | [538](/filings/0001558370-24-014255.md) | [570 d](/filings/0001558370-25-001940.md) | [536](/filings/0001558370-25-006964.md) | [544](/filings/0001558370-24-010720.md) | [560](/filings/0001558370-24-014255.md) | [580 d](/filings/0001558370-25-001940.md) | [526](/filings/0001558370-25-006964.md) | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [453](/filings/0001558370-24-014255.md) | [(355) d](/filings/0001104659-26-018169.md) | [478](/filings/0001558370-25-006964.md) | [270](/filings/0001558370-25-011059.md) | [272](/filings/0001104659-25-104506.md) | [270 d](/filings/0001104659-26-018169.md) | [262](/filings/0001104659-26-058465.md) | [268](/filings/0001104659-26-093177.md) | [266](/filings/0001104659-25-104506.md) | [271 d](/filings/0001104659-26-018169.md) | [255](/filings/0001104659-26-058465.md) | [244](/filings/0001104659-26-093177.md) |
| Operating income | $m | [23.8](/filings/0001558370-24-014255.md) | [88.7 d](/filings/0001104659-26-018169.md) | [9.7](/filings/0001558370-25-006964.md) | [16.9](/filings/0001558370-25-011059.md) | [31.1](/filings/0001104659-25-104506.md) | [(273) d](/filings/0001104659-26-018169.md) | [19.8](/filings/0001104659-26-058465.md) | [(39.7)](/filings/0001104659-26-093177.md) | [26.5](/filings/0001104659-25-104506.md) | [20.9 d](/filings/0001104659-26-018169.md) | [17.1](/filings/0001104659-26-058465.md) | [(35.2)](/filings/0001104659-26-093177.md) |
| Interest expense | $m | [38.1](/filings/0001558370-24-014255.md) | [(4.3) d](/filings/0001104659-26-018169.md) | [35.7](/filings/0001558370-25-006964.md) | [25.6](/filings/0001558370-25-011059.md) | [29.0](/filings/0001104659-25-104506.md) | [27.6 d](/filings/0001104659-26-018169.md) | [34.0](/filings/0001558370-25-006964.md) | [26.0](/filings/0001558370-25-011059.md) | [29.0](/filings/0001104659-25-104506.md) | [27.9 d](/filings/0001104659-26-018169.md) | [32.3](/filings/0001104659-26-058465.md) | [34.5](/filings/0001104659-26-093177.md) |
| Income tax | $m | [(4.6)](/filings/0001558370-24-014255.md) | [23.0 d](/filings/0001104659-26-018169.md) | [(5.2)](/filings/0001558370-25-006964.md) | [(2.7)](/filings/0001558370-25-011059.md) | [(0.3)](/filings/0001104659-25-104506.md) | [29.8 d](/filings/0001104659-26-018169.md) | [(1.6)](/filings/0001104659-26-058465.md) | [(1.1)](/filings/0001104659-26-093177.md) | [2.0](/filings/0001104659-25-104506.md) | [1.5 d](/filings/0001104659-26-018169.md) | [(9.8)](/filings/0001104659-26-058465.md) | [1.4](/filings/0001104659-26-093177.md) |
| Net income | $m | [(6.4)](/filings/0001558370-24-014255.md) | [17.8 d](/filings/0001104659-26-018169.md) | [(21.9)](/filings/0001104659-25-104506.md) | [(31.9)](/filings/0001104659-25-104506.md) | [(12.8)](/filings/0001104659-25-104506.md) | [(296) d](/filings/0001104659-26-018169.md) | [(25.0)](/filings/0001104659-26-093177.md) | [(869)](/filings/0001104659-26-093177.md) | [(150)](/filings/0001104659-25-104506.md) | [(56.3) d](/filings/0001104659-26-018169.md) | [(6.5)](/filings/0001104659-26-093177.md) | [(89.1)](/filings/0001104659-26-093177.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001558370-24-014255.md) | not reported | [(0.29)](/filings/0001558370-25-006964.md) | [(0.42)](/filings/0001558370-25-011059.md) | [(0.16)](/filings/0001104659-25-104506.md) | not reported | [(0.32)](/filings/0001104659-26-058465.md) | [(11.30)](/filings/0001104659-26-093177.md) | [(1.94)](/filings/0001104659-25-104506.md) | not reported | [(0.08)](/filings/0001104659-26-058465.md) | [(1.16)](/filings/0001104659-26-093177.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001558370-24-014255.md) | not reported | [(0.29)](/filings/0001558370-25-006964.md) | [(0.42)](/filings/0001558370-25-011059.md) | [(0.17)](/filings/0001104659-25-104506.md) | not reported | [(0.32)](/filings/0001104659-26-058465.md) | [(11.30)](/filings/0001104659-26-093177.md) | [(1.94)](/filings/0001104659-25-104506.md) | not reported | [(0.08)](/filings/0001104659-26-058465.md) | [(1.16)](/filings/0001104659-26-093177.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [215](/filings/0000075252-23-000052.md) | [243](/filings/0001558370-25-001940.md) | [245](/filings/0001558370-24-006648.md) | [244](/filings/0001558370-24-010720.md) | [45.5](/filings/0001558370-24-014255.md) | [27.6](/filings/0001104659-26-018169.md) | [59.4](/filings/0001558370-25-006964.md) | [38.3](/filings/0001558370-25-011059.md) | [32.8](/filings/0001104659-25-104506.md) | [282](/filings/0001104659-26-093177.md) | [337](/filings/0001104659-26-058465.md) | [7.7](/filings/0001104659-26-093177.md) |
| Current assets | $m | [2,130](/filings/0000075252-23-000052.md) | [2,103](/filings/0001558370-25-001940.md) | [2,236](/filings/0001558370-24-006648.md) | [2,327](/filings/0001558370-24-010720.md) | [2,117](/filings/0001558370-24-014255.md) | [2,021](/filings/0001104659-26-018169.md) | [2,206](/filings/0001558370-25-006964.md) | [2,299](/filings/0001558370-25-011059.md) | [2,132](/filings/0001104659-25-104506.md) | [548](/filings/0001104659-26-093177.md) | [589](/filings/0001104659-26-058465.md) | [271](/filings/0001104659-26-093177.md) |
| Total assets | $m | [5,124](/filings/0000075252-23-000052.md) | [5,093](/filings/0001558370-25-001940.md) | [5,208](/filings/0001558370-24-006648.md) | [5,304](/filings/0001558370-24-010720.md) | [5,081](/filings/0001558370-24-014255.md) | [4,656](/filings/0001104659-26-018169.md) | [4,856](/filings/0001558370-25-006964.md) | [4,155](/filings/0001558370-25-011059.md) | [4,036](/filings/0001104659-25-104506.md) | [2,452](/filings/0001104659-26-093177.md) | [2,416](/filings/0001104659-26-058465.md) | [2,107](/filings/0001104659-26-093177.md) |
| Current liabilities | $m | [1,732](/filings/0000075252-23-000052.md) | [1,892](/filings/0001558370-25-001940.md) | [1,933](/filings/0001558370-24-006648.md) | [2,131](/filings/0001558370-24-010720.md) | [1,934](/filings/0001558370-24-014255.md) | [1,852](/filings/0001104659-26-018169.md) | [1,960](/filings/0001558370-25-006964.md) | [2,675](/filings/0001558370-25-011059.md) | [2,466](/filings/0001104659-25-104506.md) | [947](/filings/0001104659-26-093177.md) | [1,203](/filings/0001104659-26-058465.md) | [666](/filings/0001104659-26-093177.md) |
| Total liabilities | $m | [4,237](/filings/0000075252-23-000052.md) | [4,169](/filings/0001558370-25-001940.md) | [4,313](/filings/0001558370-24-006648.md) | [4,443](/filings/0001558370-24-010720.md) | [4,207](/filings/0001558370-24-014255.md) | [4,070](/filings/0001104659-26-018169.md) | [4,285](/filings/0001558370-25-006964.md) | [4,436](/filings/0001558370-25-011059.md) | [4,466](/filings/0001104659-25-104506.md) | [2,913](/filings/0001104659-26-093177.md) | [2,881](/filings/0001104659-26-058465.md) | [2,658](/filings/0001104659-26-093177.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [207](/filings/0001558370-25-001940.md) | [208](/filings/0001558370-24-006648.md) | [211](/filings/0001558370-24-010720.md) | [42.6](/filings/0001558370-24-014255.md) | [42.9](/filings/0001104659-26-018169.md) | [49.9](/filings/0001558370-25-006964.md) | [383](/filings/0001558370-25-011059.md) | [280](/filings/0001104659-25-104506.md) | [250](/filings/0001104659-26-093177.md) | [581](/filings/0001104659-26-058465.md) | [0.0](/filings/0001104659-26-093177.md) |
| Shareholders' equity | $m | [887](/filings/0001558370-24-014255.md) | [945](/filings/0001104659-26-018169.md) | [916](/filings/0001104659-25-104506.md) | [882](/filings/0001104659-25-104506.md) | [896](/filings/0001104659-25-104506.md) | [586](/filings/0001104659-26-093177.md) | [571](/filings/0001104659-26-093177.md) | [(281)](/filings/0001104659-26-093177.md) | [(430)](/filings/0001104659-25-104506.md) | [(461)](/filings/0001104659-26-093177.md) | [(465)](/filings/0001104659-26-093177.md) | [(551)](/filings/0001104659-26-093177.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [157 d](/filings/0001558370-24-014255.md) | [112 d](/filings/0001558370-25-001940.md) | [(53.0)](/filings/0001558370-25-006964.md) | [116 d](/filings/0001558370-25-011059.md) | [27.3 d](/filings/0001104659-25-104506.md) | [71.0 d](/filings/0001558370-25-001940.md) | [(35.1)](/filings/0001558370-25-006964.md) | [37.6 d](/filings/0001558370-25-011059.md) | [(173) d](/filings/0001104659-25-104506.md) | [68.2 d](/filings/0001104659-26-018169.md) | [(50.1)](/filings/0001104659-26-058465.md) | [(26.0) d](/filings/0001104659-26-093177.md) |
| Capital expenditure | $m | [50.6](/filings/0001558370-24-014255.md) | [31.9 d](/filings/0001104659-26-018169.md) | [46.0](/filings/0001558370-24-006648.md) | [45.8](/filings/0001558370-24-010720.md) | [61.5](/filings/0001558370-24-014255.md) | [22.3 d](/filings/0001104659-26-018169.md) | [45.8](/filings/0001104659-26-058465.md) | [57.6 d](/filings/0001104659-26-093177.md) | [74.4 d](/filings/0001104659-25-104506.md) | [13.1 d](/filings/0001104659-26-018169.md) | [41.6](/filings/0001104659-26-058465.md) | [47.6 d](/filings/0001104659-26-093177.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001558370-25-006964.md) | [0.0 d](/filings/0001558370-25-011059.md) | [0.0 d](/filings/0001104659-25-104506.md) | not reported | [1.5](/filings/0001104659-26-058465.md) | [5.2 d](/filings/0001104659-26-093177.md) | [0.0 d](/filings/0001104659-25-104506.md) | [3.5 d](/filings/0001104659-26-018169.md) | [0.0](/filings/0001104659-26-058465.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [76.4](/filings/0000075252-23-000052.md) | [75.2](/filings/0001558370-24-006648.md) | [75.8](/filings/0001558370-24-010720.md) | [76.2](/filings/0001558370-24-014255.md) | [76.3](/filings/0001558370-25-006964.md) | [76.7](/filings/0001558370-25-011059.md) | [78.5](/filings/0001104659-25-104506.md) | [77.3](/filings/0001104659-26-058465.md) | [76.9](/filings/0001104659-26-093177.md) | [77.3](/filings/0001104659-25-104506.md) | [76.4](/filings/0001104659-26-058465.md) | [76.7](/filings/0001104659-26-093177.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 76,904,704 at 2026-06-30, from the cover of the [10-Q filed 2026-08-10](/filings/0001104659-26-093177.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:20 ET. No prices; not investment advice.